Antony, France, November 10 (ots/PRNewswire) - Following the
announcement that Wendel had entered exclusive negotiations with Ares
Life Sciences on October 28, 2010, with a view to selling its entire
stake (around 46%) in Stallergenes, the company's Works Council met
on November 10, 2010.
Stallergenes' Works Council having returned a positive
consultative opinion at this meeting, Wendel and Ares Life Sciences
proceeded to sign a firm transfer agreement.
It is in this context that the Stallergenes Board of Directors
met today. It took note of Ares Life Sciences' intention to pursue
the development of Stallergenes from the company's French industrial
footprint (production units and R&D centre in Antony and Amilly),
accelerate the execution of the company's strategic roadmap, as well
as further support its international development, notably in the US.
The Stallergenes Board of Directors took also note that Ares Life
Sciences does not foresee any change within Stallergenes' jobs,
salary or human resources policies.
During the meeting, Stallergenes' Chairman and CEO, Albert
Saporta, has declared: "The Ares Life Sciences team, which has
already enjoyed some major successes on the European and American
pharmaceutical markets, has a thorough understanding of the issues
related to our sector and supports our entrepreneurial vision. This
expertise will be of great benefit to the company in its current
The Board of Directors also took note of the resignation of four
of its directors (Messrs. David Darmon, Arnaud Fayet, Dirk-Jan Van
Ommeren and Compagnie Financiere de la Trinite) and decided to co-opt
Mrs Paola Ricci and Messrs Jacques Theurillat, Patrick Lee, and
Christian Chavy to replace them. These changes of board directors
remain subject to the completion of the sale of Wendel's stakeholding
in Stallergenes to Ares Life Sciences.
Given the absence of any conflict of interest with respect to the
planned sale, the Board members also decided to appoint the
accountancy firm Ledouble SA as an independent expert with a view to
issuing a fairness opinion in the context of the takeover bid that
Ares Life Sciences will submit regarding the totality of
Stallergenes' shares in application of the regulations in force. This
appointment will come into force on the date of transfer of Wendel's
Stallergenes and Ares Life Sciences' management teams will hold a
joint telephone conference on Wednesday November 17 at 6 p.m. to
answer questions related to this change in shareholding.
In application of the provisions of the AMF's General
Regulations, the Board of Directors may publish its opinion on the
value of the said takeover bid or its consequences for Stallergenes,
its shareholders and its employees on the internet once the planned
bid has been submitted to the market authority.
Stallergenes is a European biopharmaceutical company dedicated to
immunotherapy treatments for the prevention and treatment of
allergy-related respiratory diseases, such as allergic
rhinoconjunctivitis, rhinitis and asthma.
A pioneer and leader in sublingual immunotherapy treatments,
Stallergenes dedicates more than 20% of its turnover, in gross terms,
to Research and Development and is actively involved in the
development of a new therapeutic class: sublingual immunotherapy
tablets. In 2009, Stallergenes had a turnover of 193 million euros
and more than 500,000 patients were treated with Stallergenes'
Euronext Paris (Compartment B)
ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP
For further information, please visit our website:
ots Originaltext: Stallergenes
Im Internet recherchierbar: http://www.presseportal.ch
CONTACT: Contacts: Albert Saporta - Chairman and CEO.,
Tel:+33-1-55-59-20-04; Christian Thiry - Financial Director,
Tel:+33-1-55-59-20-95, e-mail: firstname.lastname@example.org;
Pressrelations: Lise Lemonnier - Communication Manager, Tel:
+33-1-55-59-20-96,e-mail: email@example.com; Investor and
analyst relations: Lucilede Fraguier - Pavie Finance, Tel: